Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

• Published in: Current treatment options in oncology Vol. 23; no. 9; pp. 1303 - 1319
• Main Authors: Huang, Wen-Kuan, Wu, Chiao-En, Wang, Shang-Yu, Chang, Ching-Fu, Chou, Wen-Chi, Chen, Jen-Shi, Yeh, Chun-Nan
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2022; Springer Nature B.V
• Subjects: Apoptosis; Cell death; Clinical trials; CTLA-4 protein; Cytotoxicity; Disease control; Disease resistance; Drug resistance; Fibroblast growth factors; Gastrointestinal cancer; Gastrointestinal tract; Imatinib; Immune checkpoint inhibitors; Inhibitor drugs; Lymphocytes T; Medicine; Medicine & Public Health; Mesenchyme; Metastases; Oncology; PD-1 protein; Protein-tyrosine kinase; Sarcoma (SH Okuno; Sarcoma (SH Okuno, Section Editor); Section Editor; Targeted cancer therapy; Therapeutic targets; Topical Collection on Sarcoma; Tumors; Regorafenib; Gastrointestinal stromal tumors; Imatinib; Sunitinib; Avapritinib; Ripretinib; Systemic treatment

Opinion statement Gastrointestinal stromal tumor (GIST), though rare, is the most common mesenchymal tumors of the gastrointestinal tract. KIT or PDGFRα mutation plays as an oncogenic driver in the majority of GISTs. Surgical resection is the only curative treatment for localized disease. The discov...